Patent for HIV drug rejected, paves way for entry of generics

https://ift.tt/b7Dp5hM The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a decade of legal battles. This decision opens the market for generic versions, promoting affordable access to treatment and potentially reducing costs. The ruling addresses concerns over 'evergreening' practices in patent filings.

https://ift.tt/XqitoWp from Times of India https://ift.tt/b7Dp5hM